First port of call for research: New strategy - see AGM...

First port of call for research:

• New strategy - see AGM presentation (latest presentation) and the strategy announcement
• Literature review on company website
• Combo Poster (this was presented at a French Leukemia Conference)

Introduction to Dr Daniel Tillett (Chief Scientific Officer) ... and responding to questions on hotcopper

• His opening post:
  • Now that I am a director of RAC it gives me the chance to introduce myself (Daniel Tillett) to all of you. I have established a company rep account here on HC to enable me to answer the questions about RAC and bisantrene that you have. I can’t discuss market sensitive information, but I have noticed reading through the threads here that there are many questions that I can answer.
    
    One of my aims is to improve communication with the shareholders and keep everyone updated on what is going on as best I can. I know it is not always easy with biotech, but I do think we can always improve.
    
• September 2019 - Dr Daniel Tillett joins Race Board
• August 2019 - Prominent Biotech investor leads investment in RACE

The following threads explore various aspects of the RACE Oncology strategy:

• Theoretical Revenue Potential of RACE Oncology 5-path Strategy
• Probability Scoring for Investment in Pre-approval Biotechs [important]
• The Priority Review Voucher

Other:

• 1993: 5 of a total of 7, 72% patients achieved total eradication of their cancer (R/R AML)